Nav: Home

Lymph node ratio may predict who lives and dies from oral cavity cancer

December 06, 2018

Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.

To answer this question, researchers from University of Colorado Cancer Center gathered the information of 149 patients treated at UCHealth University of Colorado Hospital with surgery and/or post-surgical treatments for locally-advanced oral cavity cancer between the years 2000 and 2015. In these data, they looked for patterns.

"We wanted to know if features of these patients, their tumors, or their treatment could predict survival," says first author Ding Ding, a medical student working with her research mentor, senior author Sana Karam, MD, PhD, investigator at CU Cancer Center and assistant professor of Radiation Oncology at the CU School of Medicine.

First, the researchers confirmed a handful of expected risk factors: As seen in many previous studies, being nonwhite, uninsured or insured by Medicaid, having a larger primary tumor, having "margins" around the tumor that tested positive for cancer even after surgery, or having tumors that had already invaded surrounding tissues predicted shorter overall survival.

Another factor commonly used in models predicting cancer risk is the extent of lymph node involvement.

"The current nodal staging system for oral cavity cancer is based on the size, number, laterality, and spread of the tumor outside the wall of the involved lymph nodes," Ding says. "In other types of cancers such as breast cancer, researchers have been exploring another measure of lymph node involvement, namely whether the ratio of surgically removed lymph nodes that are positive for cancer can predict treatment outcomes. We wondered if lymph node ratio, or LNR, could be a predictor of survival in oral cavity cancer, as well."

The 149 patients studied had a median 29 lymph nodes removed during surgery. About 9 percent of these lymph nodes were positive for cancer. Of course, this meant that some patients had LNR above 10 percent, while others had especially low or even zero LNR. And it turned out that patients with LNR greater than 10 percent had about 2.5 times greater risk of cancer recurrence and 2.7 times greater risk of death than patients with LNR below 10 percent. Results are published in the journal JAMA Otolaryngology.

"In our study, LNR appeared to be more predictive of patient outcomes than the traditional method of lymph node staging. Larger scale studies are needed to verify these findings and it might be worth exploring ways to incorporate LNR into the current model for evaluating recurrence risks," Ding says.

Patients with aggressive disease should receive more intensive chemotherapy and radiation after surgery, whereas others with less aggressive disease often forgo the full extent of these treatments. But who are these high-risk patients? The current study adds to a growing body of evidence supporting the use of LNR to identify patients at most risk for recurrence and death from locally-advanced oral cavity cancer.
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

The Emperor of All Maladies: A Biography of Cancer
by Siddhartha Mukherjee (Author)

The Truth about Cancer: What You Need to Know about Cancer's History, Treatment, and Prevention
by Ty M. Bollinger (Author)

Chris Beat Cancer: A Comprehensive Plan for Healing Naturally
by Chris Wark (Author)

The Cancer-Fighting Kitchen, Second Edition: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery
by Rebecca Katz (Author), Mat Edelson (Author)

Anticancer: A New Way of Life
by David Servan-Schreiber MD PhD (Author)

F*ck Cancer: A totally inappropriate self-affirming adult coloring book (Totally Inappropriate Series) (Volume 4)
by Jen Meyers (Author)

The Breakthrough: Immunotherapy and the Race to Cure Cancer
by Charles Graeber (Author)

The Biology of Cancer, 2nd Edition
by Robert A. Weinberg (Author)

Physicians' Cancer Chemotherapy Drug Manual 2019
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)

Cancer: Step Outside the Box
by Ty M. Bollinger (Author)

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Approaching With Kindness
We often forget to say the words "thank you." But can those two words change how you — and those around you — look at the world? This hour, TED speakers on the power of gratitude and appreciation. Guests include author AJ Jacobs, author and former baseball player Mike Robbins, Dr. Laura Trice, Professor of Management Christine Porath, and former Danish politician Özlem Cekic.
Now Playing: Science for the People

#509 Anisogamy: The Beginning of Male and Female
This week we discuss how the sperm and egg came to be, and how a difference of reproductive interest has led to sexual conflict in bed bugs. We'll be speaking with Dr. Geoff Parker, an evolutionary biologist credited with developing a theory to explain the evolution of two sexes, about anisogamy, sexual reproduction through the fusion of two different gametes: the egg and the sperm. Then we'll speak with Dr. Roberto Pereira, research scientist in urban entomology at the University of Florida, about traumatic insemination in bed bugs.